Leading Edge Pharms Inc, a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced yesterday that it has named Dr Daniel Holsworth as its new chief science officer.

Dr Holsworth joins the company with 25 years of experience as a drug discovery and development expert, entrepreneur and regulatory affairs professional. He has extensive experience in treating inflammatory skin conditions. During his tenure with CA Botana International, Dr Holsworth formulated therapeutic skin care products employing stem cell development pathway biology and peptide chemistry. He holds 25 patents for his discoveries. Earlier, Dr Holsworth was an associate research fellow medicinal chemist at Pfizer, co-founder and head of Chemistry at ODIN Therapeutics AS and Technical Advisor for CA Botana International.

David Chadwick, CEO of Leading Edge Pharms Inc, said, 'One of our key differentiators has always been a commitment to clinical thoroughness, even as many CBD products are being rushed to market to capitalise on a new trend. Dan has been an important part of the LEP team for two years as a consultant and was instrumental in the development of Silvidiol, our liposomal CBD compound and delivery system. Now, as CSO, Dan will lead our research and development efforts and be directly responsible for the formulation of many exciting new products LEP will be releasing in 2019. We look forward to working closely together to advance the scientific work being done within the cannabis industry.'